Physician profile
Daniel J Glatt
NPI 1649228917
$44,691.77
in general payments reported to CMS, 2019-2025
66 companies · $2,753 in 2025
The $2,753 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $10K · 2021: $7,955 · 2022: $4,998 · 2023: $4,580 · 2024: $1,840 · 2025: $2,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,940 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,360 · Travel and Lodging: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,940.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,360.00 |
| Travel and Lodging | $871.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $16,450.61 | 2019-2025 | Vivitrol, Vivitrol |
| Indivior INC. | $9,568.41 | 2019-2025 | Sublocade |
| Biodelivery Sciences International, INC. | $5,964.99 | 2019-2021 | |
| Abbvie INC. | $1,706.07 | 2019-2025 | |
| Novo Nordisk INC | $956.93 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $935.86 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $871.09 | 2019-2025 | Belbuca, Xtampza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $761.93 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $533.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $491.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $478.60 | 2019-2025 | Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $384.47 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $327.35 | 2019-2021 | |
| Astellas Pharma US INC | $320.34 | 2019-2023 | Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $316.11 | 2019-2025 | Rexulti, Abilify Maintena |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $268.62 | 2019-2023 | Belsomra |
| Allergan, INC. | $263.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $228.39 | 2019-2022 | |
| Amgen INC. | $224.57 | 2019-2020 | |
| Redhill Biopharma INC. | $216.43 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Glaxosmithkline, LLC. | $211.98 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $209.90 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.41 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $163.52 | 2022-2024 | Quviviq |
| Lundbeck LLC | $162.55 | 2020-2023 | Rexulti |
| Seqirus USA INC | $149.04 | 2021-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Fluad |
| Axsome Therapeutics, INC. | $146.46 | 2023-2024 | Sunosi, Auvelity |
| Bausch Health US, LLC | $132.16 | 2019-2023 | Aplenzin |
| Esperion Therapeutics, INC. | $125.13 | 2023-2025 | Nexletol |
| Eisai INC. | $120.18 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $119.57 | 2019-2021 | |
| Orexo US, INC. | $100.74 | 2019-2020 | |
| Verity Pharmaceuticals INC. | $99.75 | 2024-2025 | Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $95.72 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $95.14 | 2025 | |
| Edwards Lifesciences Corporation | $93.47 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Biohaven Pharmaceuticals, INC. | $93.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $87.84 | 2022-2025 | Eliquis |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Braeburn INC. | $83.54 | 2023-2024 | Brixadi |
| Medicure Pharma INC. | $62.93 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $60.12 | 2022-2025 | Zoryve |
| Vanda Pharmaceuticals INC. | $52.53 | 2023-2024 | Hetlioz, Fanapt |
| Exact Sciences Corporation | $51.90 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Covis Pharma Gmbh | $49.92 | 2022 | |
| Boston Scientific Corporation | $46.56 | 2023 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $44.52 | 2022 | |
| Assertio Therapeutics, INC. | $43.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.22 | 2020-2021 | |
| Forte Bio-Pharma LLC | $36.58 | 2021 | |
| Hikma Pharmaceuticals USA | $34.82 | 2021-2022 | |
| Mdd US Operations, LLC | $34.59 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $31.19 | 2022 | |
| Phathom Pharmaceuticals, INC. | $25.95 | 2024 | Voquezna |
| Almatica Pharma LLC | $24.21 | 2024 | Loreev Xr |
| Alfasigma USA, INC. | $22.73 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.50 | 2021 | |
| Neurocrine Biosciences, INC. | $21.66 | 2025 | |
| Abbott Laboratories | $21.21 | 2023 | Proclaim |
| Kaleo, INC. | $20.63 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.12 | 2020 | |
| Masimo Corporation | $17.38 | 2024 | Bridge, Patient Safetynet System |
| Antares Pharma, INC. | $15.76 | 2020 | |
| Circassia INC. | $15.12 | 2020 | |
| Horizon Therapeutics Plc | $14.64 | 2019 | |
| Nevro Corp. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Glatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.